Dr. Jabs is an internationally recognized expert in clinical trials and evidence-based medicine. He has held NIH funding continuously for over 30 years. He has chaired numerous clinical trials on the treatment of uveitis, and its ocular complications.
He is the Chair of the international, NIH-funded multicenter, comparative effectiveness clinical trial, the ADVISE Trial, on the use of an anti-TNF biologic in the treatment of severe uveitides. He is the Research Group Chair of the international, NIH-funded multicenter clinical trials, the MERIT and POINT Trials, on the treatment of uveitic macular edema. He was the Chair of the international, NIH-funded, multicenter comparative effectiveness clinical trial, the MUST Trial, on the use of immunosuppression for treatment of severe uveitides.
Dr. Jabs also chaired a long-term, NIH-funded, multicenter, cohort study on the occurrence of ocular infections in immune compromised persons. He chairs the Standardization of Uveitis (SUN) Working Group, which is an international group of uveitis experts dedicated to improving clinical research in the field of Uveitis. The SUN Working Group’s current project is to define classification criteria to diagnose the leading 25 uveitides.